amendment:
  amendment_details: '<p>Amendment Details:</p>

    <p>This protocol has been amended previously. Details of prior amendments are
    presented in Prior Protocol Amendment(s).}</p>'
  robustness_impact: false
  robustness_impact_reason: ''
  safety_impact: false
  safety_impact_reason: ''
miscellaneous:
  medical_expert_contact: '<p>SAE Reporting Method: Report Serious Adverse Events
    to the sponsor via provided forms. Refer to Section 9.4 for detailed reporting
    instructions.</p>

    <p></p>'
  sae_reporting_method: ''
  sponsor_signatory: '<p>Sponsor Signatory:   Signature block and date on file at
    Eli Lilly and Company</p>'
title_page:
  amendment_details: ''
  amendment_identifier: 'H2Q-MC-LXXT(c)

    '
  amendment_scope: 'Global

    '
  compound_codes: 'LY246708

    '
  compound_names: 'Xanomeline

    '
  manufacturer_name_and_address: ''
  medical_expert_contact: ''
  original_protocol: 'No

    '
  regulatory_agency_identifiers: 'NCTA12313212



    '
  sae_reporting_method: ''
  sponsor_approval_date: ''
  sponsor_confidentiality: ''
  sponsor_name_and_address: 'Eli Lilly and Company

    Lilly Corporate Center

    Indianapolis, IN 46285

    '
  sponsor_signatory: ''
